Kala Pharmaceuticals, Inc.(KALA), is a biopharmaceutical corporation located in Watertown, Massachusetts which specializes in the research, development, and commercialization of therapies using its proprietary formulation technology platform. Founded in 2009, the company is dedicated to advancing the treatment of eye diseases.
The company’s main product is Inveltys, which is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery. Moreover, it has also developed a product known as Eysuvis, for the short-term treatment of the signs and symptoms of dry eye disease, which was approved by the FDA in October 2020. These treatments are designed to enhance penetration into the eye's tear film, aiming to provide relief to patients suffering from eye diseases.
Kala’s innovative drug delivery platform, known as AMPPLIFY, uses nanoparticle technology. This technology maximizes the potency and duration of therapeutic effect. The technology was designed to address the major challenge of ocular drug delivery, which is getting sufficient quantities of the medicine across the eye's tear film to reach the target tissue.
Kala Pharmaceuticals was initially a spinoff from renowned Massachusetts Institute of Technology (MIT). The company’s evolution has involved a series of successful funding rounds, with an eventual Initial Public Offering (IPO) in July 2017, providing a range of funding to fuel their research and product development programs.
The management team at Kala Pharmaceuticals is composed of healthcare industry professionals with extensive expertise in the pharmaceutical and optometry industry. The goal of the company is to utilize its proprietary technology to improve both the potency and the frequency of treatment required, offering promising advances for unmet medical needs.
In the future, Kala Pharmaceuticals intends to apply the AMPPLIFY Drug Delivery Technology to a range of other ocular diseases and conditions beyond dry eye and post-operative inflammation. Despite being a relatively young establishment in the pharmaceutical industry, Kala Pharmaceuticals, Inc. continues to make strides in the research and development of innovative solutions for eye diseases, thereby positively impacting the quality of life for patients worldwide.